Loading...
By Joe Elia
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Three companies that supply insulin in the U.S. are accused of conspiring to set increasingly higher prices for their product, the New York Times reports.
In a class action lawsuit, Sanofi, Novo Nordisk, and Eli Lilly are alleged to have raised their insulin prices "in an astounding and inexplicable manner," driving prescription prices from $25 to over $300 within a 5-year span. The suit alleges that some drug distributors — pharmacy benefit managers (PBMs) — are complicit, but they are not named in the complaint.
The scheme involves the companies' offering insulin to PBMs at prices lower than the list — or "benchmark" — price. Then, "the PBMs pocket a percentage of the difference between the reported benchmark price and the undisclosed real price" to the PBM.
The three companies all defended their actions in statements reported by the Times.
Comment
LINK(S):
Class action complaint (Free PDF)
New York Times story (Free)
Background: Physician's First Watch coverage of insulin pricing (Free)